Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
D

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/Targeted Therapy, What's the "Right" Frontline Therapy, TMB, Wild Type Disease, Potential Biomarker for Long-Term Benefit

By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
44 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley
Skin
14:32

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

32 views
06:35

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

21 views
21:19

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Xth Eurasian Hematology-Oncology Congress

S. Seber

252 views
05:25

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

29 views
15:44

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

44 views